GLP-1 clinical trials are some of the most challenging for participants to complete, with side effects, lifestyle disruptions, and stigma often leading to early withdrawal. This case study explores how MRN addressed these issues within a Phase 2 GLP-1 program by deploying specialised Patient Navigators to provide continuous telemedicine support. Through personalised nutritional guidance, symptom management, and mental-health reassurance, participants received the consistency and care needed to remain engaged throughout the study.
This approach not only improved retention and reduced dropout rates, but it also strengthened collaboration with sites through real-time visit reporting and aligned oversight. The success of this model is now shaping planning for global Phase 3 studies launching in 2026, where MRN’s combination of remote support and in-home visits aims to deliver a scalable, participant-centred framework for advancing GLP-1 research across diverse countries and patient populations.
Key outcomes:
- Improved participant retention, with fewer early withdrawals as participants received regular one-to-one guidance from qualified healthcare professionals.
- Better symptom management through nutritional and lifestyle coaching delivered remotely by trained HCPs.
- Enhanced communication with sites, as visit reports were shared directly with investigators in real time.
- Positive participant feedback, with participants reporting the support as beneficial to both wellbeing and adherence.
This model demonstrated how specialized, flexible support can strengthen participant retention and data quality in GLP-1 studies, without adding burden to sites or participants.
Download the full case study below.